Clinical Trial Update: An Exploratory Clinical Study Evaluating Allogeneic iPSC-derived Pancreatic Islet Cells (CRG-002) for the Treatment of Diabetic Patients With Hypoglycemia Unawareness or Severe Hypoglycemic Events [EARLY_Phase 1]

View source ↗

Summary

An early-phase exploratory study evaluating CRG-002, an allogeneic iPSC-derived pancreatic islet cell therapy, for treating hypoglycemia unawareness or severe h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus
• Type 3c Diabetes Mellitus

Drugs mentioned

• CRG-002 (allogeneic iPSC-derived pancreatic islet cells)

Snippet

Sponsor: Celregen Therapeutics | Conditions: T1DM - Type 1 Diabetes Mellitus, Pancreatogenic Diabetes Mellitus | EARLY_Phase 1 | Status: ENROLLING_BY_INVITATION